INGELHEIM, Germany - Tuesday, May 17th 2016 [ME NewsWire]
A new analysis of Phase III INPULSIS® trials reinforces OFEV®’s slowing of disease progression in a composite endpoint involving lung function decline (FVC decrease >10%) and death1
In a separate analysis of the INPULSIS® trials, OFEV® significantly reduced the risk of acute exacerbations reported as serious adverse events2
One-year data from post-marketing surveillance, including real-world clinical data of 6,700 patients, further confirms the safety profile of OFEV® seen in studies3
(BUSINESS WIRE)-- New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).1-4 In total, Boehringer Ingelheim presented 12 IPF-related abstracts at ATS, including further analyses of the INPULSIS® trials, which add to the growing body of evidence reinforcing the clinical benefit of OFEV® across a broad range of patients, by showing that:
OFEV® slowed disease progression in a composite endpoint of lung function decline (forced vital capacity, or FVC, decrease ≥10%) and death.1
OFEV® slowed lung function decline independent of disease severity as measured by GAP stage (patient’s gender, age or disease physiology) at baseline.4
OFEV® significantly reduced the risk of a first investigator-reported acute exacerbation (reported as a serious adverse event) by 43% versus placebo based on pooled data from the INPULSIS® trials.2
One-year data from post-marketing surveillance, including real-world clinical data from 6,700 patients taking OFEV®, further confirmed the safety and tolerability profile seen in studies.3
“IPF progression is variable and unpredictable, but, over time, the lung function of patients gradually and irreversibly declines,” said Imre Noth, M.D., Professor of Medicine and Director of the Interstitial Lung Disease Program at the University of Chicago. “Ongoing analyses of the Phase III INPULSIS® trials along with real-world data provide additional support for the safety and efficacy of treatment with OFEV®. As slowing disease progression is an important treatment goal, these data provide support for the benefit to IPF patients regardless of disease severity.”
The new analyses from the pooled Phase III INPULSIS® trials showed that:
OFEV® significantly reduced the risk of disease progression by 40% (27.1%, OFEV® vs. 41.4%, placebo; p<0.0001), as measured by a composite endpoint of worsening in lung function (absolute decline in FVC ≥10%) or death over 52 weeks. Furthermore, the analyses showed there was a consistent reduction in disease progression across a range of patients defined by baseline FVC.1 (Abstract A2693)
OFEV®’s clinical benefit was consistent across subgroups. OFEV® slowed a decline in lung function regardless of the patient’s GAP stage (gender, age and disease physiology) at baseline.4 (Abstract A2691)
OFEV® significantly reduced the risk for time to first acute exacerbations reported by investigators as a serious adverse event by 43% (3.6%, OFEV® vs. 6.1%, placebo; p=0.0476) and 70% (1.6%, OFEV® vs. 5%, placebo; p=0.0019) for serious adverse events adjudicated as confirmed or suspected acute exacerbations. Acute exacerbations reported as serious adverse events were associated with a higher risk of death than acute exacerbations reported as non-serious adverse events.2 (Abstract A2690)
One-year data on adverse events collected from more than 6,700 U.S. OFEV® patients from post-marketing surveillance, including real-world clinical data, was consistent with those seen in the pivotal clinical trials. No new safety concerns or unexpected safety signals were observed.3 (Abstract A2692)
“Boehringer Ingelheim is committed to furthering science that addresses the unmet needs of people with rare diseases where limited treatments exist,” said Dr William Mezzanotte, Therapy Area Head, Respiratory Medicine. “Already, more than 10,000 patients worldwide have received treatment with OFEV® to date, and we’re continually working to advance the understanding of IPF through our clinical trial program and ongoing research of OFEV® in the real-world clinical setting.”
The abstracts presented at the conference can be accessed by searching for the abstract numbers listed here: http://199.115.242.3/slidecenter/ats2016/planner
~ ENDS ~
Please click on the link below for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/new-presentations-ats-2016-reinforce-ofev-nintedanib
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Kristin Jakobs
Phone: +49 6132 77 144553
Fax: +49 6132 – 77 6601
Email: press@boehringeringelheim.com
or
More information
www.boehringer-ingelheim.com
Permalink: http://me-newswire.net/news/17898/en
A new analysis of Phase III INPULSIS® trials reinforces OFEV®’s slowing of disease progression in a composite endpoint involving lung function decline (FVC decrease >10%) and death1
In a separate analysis of the INPULSIS® trials, OFEV® significantly reduced the risk of acute exacerbations reported as serious adverse events2
One-year data from post-marketing surveillance, including real-world clinical data of 6,700 patients, further confirms the safety profile of OFEV® seen in studies3
(BUSINESS WIRE)-- New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).1-4 In total, Boehringer Ingelheim presented 12 IPF-related abstracts at ATS, including further analyses of the INPULSIS® trials, which add to the growing body of evidence reinforcing the clinical benefit of OFEV® across a broad range of patients, by showing that:
OFEV® slowed disease progression in a composite endpoint of lung function decline (forced vital capacity, or FVC, decrease ≥10%) and death.1
OFEV® slowed lung function decline independent of disease severity as measured by GAP stage (patient’s gender, age or disease physiology) at baseline.4
OFEV® significantly reduced the risk of a first investigator-reported acute exacerbation (reported as a serious adverse event) by 43% versus placebo based on pooled data from the INPULSIS® trials.2
One-year data from post-marketing surveillance, including real-world clinical data from 6,700 patients taking OFEV®, further confirmed the safety and tolerability profile seen in studies.3
“IPF progression is variable and unpredictable, but, over time, the lung function of patients gradually and irreversibly declines,” said Imre Noth, M.D., Professor of Medicine and Director of the Interstitial Lung Disease Program at the University of Chicago. “Ongoing analyses of the Phase III INPULSIS® trials along with real-world data provide additional support for the safety and efficacy of treatment with OFEV®. As slowing disease progression is an important treatment goal, these data provide support for the benefit to IPF patients regardless of disease severity.”
The new analyses from the pooled Phase III INPULSIS® trials showed that:
OFEV® significantly reduced the risk of disease progression by 40% (27.1%, OFEV® vs. 41.4%, placebo; p<0.0001), as measured by a composite endpoint of worsening in lung function (absolute decline in FVC ≥10%) or death over 52 weeks. Furthermore, the analyses showed there was a consistent reduction in disease progression across a range of patients defined by baseline FVC.1 (Abstract A2693)
OFEV®’s clinical benefit was consistent across subgroups. OFEV® slowed a decline in lung function regardless of the patient’s GAP stage (gender, age and disease physiology) at baseline.4 (Abstract A2691)
OFEV® significantly reduced the risk for time to first acute exacerbations reported by investigators as a serious adverse event by 43% (3.6%, OFEV® vs. 6.1%, placebo; p=0.0476) and 70% (1.6%, OFEV® vs. 5%, placebo; p=0.0019) for serious adverse events adjudicated as confirmed or suspected acute exacerbations. Acute exacerbations reported as serious adverse events were associated with a higher risk of death than acute exacerbations reported as non-serious adverse events.2 (Abstract A2690)
One-year data on adverse events collected from more than 6,700 U.S. OFEV® patients from post-marketing surveillance, including real-world clinical data, was consistent with those seen in the pivotal clinical trials. No new safety concerns or unexpected safety signals were observed.3 (Abstract A2692)
“Boehringer Ingelheim is committed to furthering science that addresses the unmet needs of people with rare diseases where limited treatments exist,” said Dr William Mezzanotte, Therapy Area Head, Respiratory Medicine. “Already, more than 10,000 patients worldwide have received treatment with OFEV® to date, and we’re continually working to advance the understanding of IPF through our clinical trial program and ongoing research of OFEV® in the real-world clinical setting.”
The abstracts presented at the conference can be accessed by searching for the abstract numbers listed here: http://199.115.242.3/slidecenter/ats2016/planner
~ ENDS ~
Please click on the link below for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/new-presentations-ats-2016-reinforce-ofev-nintedanib
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Kristin Jakobs
Phone: +49 6132 77 144553
Fax: +49 6132 – 77 6601
Email: press@boehringeringelheim.com
or
More information
www.boehringer-ingelheim.com
Permalink: http://me-newswire.net/news/17898/en